| 영문 | alpha particles | 한글 | 알파입자 |
|---|---|---|---|
| 설명 | 원자에 정상보다 과다, 과소한 중성자나 양자를 가지고 있는 경우에 원자가 안정되기 위해서 붕괴가 생긴다. 이런 붕괴에는 다음과 같은 3가지 방법이 있다. 알파－붕괴는 알파입자를 방출하여 안정되는 법, 즉 원자번호는 2씩 감소하고 질량수는 4씩 감소한다. 알파입자란 알파붕괴에 의해서 생기는 헬륨의 핵과 같은 입자를 말한다. |
||
| 영문 | alpha-fetoprotein | 한글 | 알파태아단백 |
|---|---|---|---|
| 설명 | 태아의 간조직이나 소화기관에서 만들어지는 단백질. 태아기나 임산부에서 정상적으로 존재한다. 그러나 간암세포나 생식세포에 관련된 종양에서도 만들어져 이런 질병이 존재할 때에는 임산부나 태아가 아니더라도 조직이나 혈액에 나타나게 된다. 임상적으로는 간암이나 생식세포 종양의 발견과 치료효과 판정에 이용되고, 또 임신 16~18주에 산모의 혈액에서 이단백질의 양을 측정하여 태아의 비정상적인 발달을 발견할 수 있다. |
||
| DOPA, dopa | dihydroxyphenylalanine |
|---|---|
| L-DOPA, | L-dopa levodopa, levo-3, 4-dihydroxyphenylalanine |
| DDC | L-Dopa De-Carboxylase |
| DOPA | 3,4-Dihydr-Oxy-Phenyl-Alanine |
| MPMP | 10[(1-methyl-3-piperidinyl)-methyl]-1OH-phenothiazine |
| (18)F-DOPA | 6-[(18)F]fluoro-L-DOPA |
|---|---|
| alpha-MPT | alpha-methyl-L-p-tyrosine |
| alpha-MT | Alpha-methyl tyrosine |
| alpha-Me-5-HT | alpha-Methyl-5-hydroxytryptamine |
| alpha-MT | alpha-methyl paratyrosine |
methyl group
| alpha methyl dopa | <drug> An antihypertensive drug, preferred in pregnant patients. (18 Nov 1997) |
|---|
| alpha-(4-O-methyl)-D-glucuronidase | <enzyme> Removes 4-o-methyl-glucopyranosyl uronic acid residues from the 2-position of fungal cell wall xylans Registry number: EC 3.2.1.- Synonym: 4-o-methyl-glucuronidase (26 Jun 1999) |
|---|---|
| alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid | <chemical> Alpha-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid. An ibotenic acid homolog and glutamate agonist. The compound is the defining agonist for the ampa subtype of glutamate receptors (receptors, ampa). It has been used as a radionuclide imaging agent but is more commonly used as an experimental tool in cell biological studies. Pharmacological action: excitatory amino acid agonists. Chemical name: 4-Isoxazolepropanoic acid, alpha-amino-2,3-dihydro-5-methyl-3-oxo- (12 Dec 1998) |
| (4-fluorophenyl)-alpha-methyl-5-benzoxazole methylamine | Amine derivative of flunoxaprofen. Pharmacological action: fluorescent dye Synonym: s-flopa (26 Jun 1999) |
| decarboxylated dopa | <drug> A catecholamine neurotransmitter and hormone (153 D), formed by decarboxylation of dehydroxyphenylalanine (dopa). A precursor of adrenaline and noradrenaline. Pharmacologic action: 1. Precursor of norepinephrine 2. Stimulates dopaminergic, alpha and beta-1 adrenergic receptors: 3. Dopaminergic (1-2 mcg/kg per min): cerebral, renal, and mesenteric vasodilation increase urine output 4. Mixed alpha and beta-1 (2-10 mcg/kg per min): increases cardiac ouput with moderate increase systemic vascular resistance 5. Predominantly alpha (>20 mcg/kg per min): increases systemic vascular resistance Uses: 1. Treat hypotension associated with bradycardia 2. Stimulate cardiac output and urine output Dose: 1. Start infusion at 1-5 mcg/kg per min and titrate to effect. 2. Use the lowest dose that provides the desired hemodynamic improvement. 3. Do not exceed 20 mcg/kg per min. Potential complications: 1. May increase pulmonary pressure and worsen pulmonary congestion. 2. May increase myocardial work without improving coronary blood flow, exacerbating myocardial ischemia 3. Stimulates heart rate and may cause supraventricular or ventricular arrhythmias (15 Mar 2000) |
| dopa | An amino acid derived from the amino acid tyrosine. It is formed as the first intermediate in the production of dopamine, a neurotransmitter. (09 Oct 1997) |
| dopa decarboxylase | <enzyme> One of the aromatic-l-amino-acid decarboxylases, this enzyme is responsible for the conversion of dopa to dopamine. It is of clinical importance in the treatment of parkinson's disease. Registry number: EC 4.1.1.- (12 Dec 1998) |
| DOPA dioxygenase | <enzyme> Key enzyme in betalain biosynthesis pathway of amanita muscaria; genbank y12886 Registry number: EC 1.14.99.- Synonym: dopa-4,5-dioxygenase, doda gene product (26 Jun 1999) |
| dopa oxidase | Provisional name given the enzyme(s) catalyzing the formation of melanins from dopa; it now appears that the copper-containing monophenol monooxygenases and/or catechol oxidases are responsible for the oxidation of l-tyrosine to dopa and dopa quinone. (05 Mar 2000) |
| dopa quinone | An oxidation product of dopa and an intermediate in the formation of melanin from tyrosine. (05 Mar 2000) |
| dopa reaction | A dark staining observed in fresh tissue sections to which a solution of dopa has been applied, presumably due to the presence of dopa oxidase in the protoplasm of certain cells. Synonym: Bloch's reaction. (05 Mar 2000) |
| dopa-responsive dystonia | A condition successfully treated with drugs. Typically, DRD begins in childhood or adolescence with progressive difficulty in walking and, in some cases, spasticity. Segawa's dystonia is an important variant of DRD. In Segawa's dystonia, the symptoms fluctuate during the day from relative mobility in the morning to increasingly worse disability in the afternoon and evening as well as after exercise. Some scientists feel DRD is not only rare but also rarely diagnosed since it mimics many of the symptoms of cerebral palsy. (12 Dec 1998) |
| Dopa-tyrosine sulfotransferase | <enzyme> Active towards tyrosine and dopa isomers except dl-ortho-tyrosine; isolated from rat liver; genbank u38419 Registry number: EC 2.8.2.- (26 Jun 1999) |
| dystonia, dopa-responsive | A condition successfully treated with drugs. Typically, DRD begins in childhood or adolescence with progressive difficulty in walking and, in some cases, spasticity. Segawa's dystonia is an important variant of DRD. In Segawa's dystonia, the symptoms fluctuate during the day from relative mobility in the morning to increasingly worse disability in the afternoon and evening as well as after exercise. Some scientists feel DRD is not only rare but also rarely diagnosed since it mimics many of the symptoms of cerebral palsy. (12 Dec 1998) |
| l-dopa | <chemical> The naturally occurring form of dopa and the immediate precursor of dopamine. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to dopamine. It is used for the treatment of parkinsonism and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. Pharmacological action: antiparkinson agents, dopamine agents. (12 Dec 1998) |
| L-dopa peroxidase | <enzyme> Found in human erythrocytes associated with catalase Registry number: EC 1.11.- (26 Jun 1999) |
| alpha methyl dopa | antihypertensive drug (trade name Aldomet) used in the treatment of high blood pressure |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|